mk-2206
Mantle Cell Lymphoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
162 Active assets in the Mantle Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide Ruijin Hospital | Phase 4 | BBB |
Cis-Diamminedichloroplatinum Ii National Cancer Institute (NCI) | Phase 4 | BBB |
Irinotecan University of Michigan Rogel Cancer Center | Phase 2 | BBB |
Vincristine Sulfate M.D. Anderson Cancer Center | Phase 2 | BBB |
Busulfanum City of Hope Medical Center | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
mk-2206 is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative · Phase 2
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →